Van Den Berg H M, Fischer K, Roosendaal G, Mauser-Bunschoten E P
Van Creveld Clinic, National Haemophilia Center, University Hospital Utrecht, The Netherlands.
Haemophilia. 1998 Jul;4(4):418-20. doi: 10.1046/j.1365-2516.1998.440418.x.
Port-A-Caths have been used increasingly in children with severe haemophilia. In non-inhibitor patients where Port-a-Caths were used to facilitate long-term prophylaxis, the infection rate is rather low and ranges in the various studies from 0 to 29%, with a median follow-up time of about 27 months. Patients that received the Port-A-Cath for the induction of immune tolerance (inhibitor patients) have a high infection rate of 50% to 83%. Although this percentage is high, good venous access is extremely important, especially in this group. The number of both inhibitor and non-inhibitor patients in the studies are very small, and a prospective survey is important to obtain more adequate data.
植入式静脉输液港在重度血友病儿童中的使用越来越多。在使用植入式静脉输液港以促进长期预防治疗的非抑制物患者中,感染率相当低,在各项研究中为0%至29%,中位随访时间约为27个月。接受植入式静脉输液港以诱导免疫耐受(有抑制物患者)的患者感染率高达50%至83%。尽管这个百分比很高,但良好的静脉通路极其重要,尤其是在这组患者中。研究中的有抑制物和无抑制物患者数量都非常少,因此进行前瞻性调查以获取更充分的数据很重要。